Pulpitis
diseaseOn this page
Also known as dental pulp inflammationinflammation of dental pulp
Summary
Pulpitis (MONDO:0006937) is a disease with 1 GWAS associations across 6 studies and 69 clinical trials. Top therapeutic interventions include prednisolone, articaine, and hydrogen peroxide. A subtype of dental pulp disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- GWAS associations: 1
- Clinical trials: 69
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | pulpitis |
| Mondo ID | MONDO:0006937 |
| EFO | EFO:1001139 |
| MeSH | D011671 |
| DOID | DOID:11121 |
| ICD-10-CM | K04.0 |
| ICD-11 | 576344431 |
| SNOMED CT | 32620007 |
| UMLS | C0034103 |
| MedGen | 19580 |
| MedDRA | 10037463 |
| Is cancer (heuristic) | no |
Also known as: dental pulp inflammation · inflammation of dental pulp
Data availability: 1 GWAS association (6 studies).
Disease family
This is a subtype of dental pulp disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › skeletal system disorder › tooth disorder › dental pulp disorder › pulpitis
Related subtypes (6): pulp degeneration, dental pulp necrosis, pulp erosion, dental pulp calcification, exposure, dental pulp, secondary dentine
Genetics & variants
GWAS landscape
1 GWAS associations across 6 studies. Top hits map to 0 distinct genes (as reported by GWAS).
Top associations by p-value
| rsID | p-value | Gene | Risk allele | Odds ratio |
|---|---|---|---|---|
| rs183067431 | 3e-08 | SPATA2P1 - RN7SKP6 | ? |
Top studies (by case count)
| Study | Lead author | Year | Cases | Controls | Title |
|---|---|---|---|---|---|
| GCST90478245 | Verma A | 2024 | 11,523 | 427,824 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90478244 | Verma A | 2024 | 5,068 | 111,016 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90480854 | Verma A | 2024 | 5,068 | 111,016 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90478243 | Verma A | 2024 | 2,346 | 55,130 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90651626 | Liu TY | 2025 | 2,019 | 208,919 | Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population. |
| GCST90482109 | Verma A | 2024 | 251 | 6,393 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
Variant details and genetic-evidence tiers
Tier distribution (top 50 variants)
| Tier | Variants |
|---|---|
| Tier 1: coding | 0 |
| Tier 2: splice/UTR | 0 |
| Tier 3: regulatory | 0 |
| Tier 4: intronic/intergenic | 1 |
MAF distribution
| Bucket | Variants |
|---|---|
| common (>=0.05) | 0 |
| low_freq (0.01-0.05) | 0 |
| rare (<0.01) | 0 |
| unknown | 1 |
Functional consequences
| Consequence | Count |
|---|---|
| intergenic_variant | 1 |
Top variants
| rsID | Chr | Pos | Alleles | MAF | Consequence | Gene | p-value | Tier |
|---|---|---|---|---|---|---|---|---|
| rs183067431 | 13 | 56761062 | A>T | intergenic_variant | SPATA2P1 - RN7SKP6 | 3e-08 | Tier 4: intronic/intergenic |
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
0 approved, 8 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Articaine | Phase 3 (in late-stage trials) |
| Calcium | Phase 3 (in late-stage trials) |
| Epinephrine | Phase 3 (in late-stage trials) |
| Ibuprofen | Phase 3 (in late-stage trials) |
| Lidocaine | Phase 3 (in late-stage trials) |
| Methylprednisolone | Phase 3 (in late-stage trials) |
| Prednisolone | Phase 3 (in late-stage trials) |
| Sodium Bicarbonate | Phase 3 (in late-stage trials) |
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Acetaminophen, Bromelains, Bupivacaine, Fentanyl, Mannitol, Poliglusam, Polihexanide, Sodium Chloride, Sufentanil.
Clinical trials & evidence
Clinical trials
Clinical trials: 69.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 57 |
| PHASE4 | 4 |
| PHASE3 | 2 |
| PHASE1/PHASE2 | 2 |
| PHASE2 | 2 |
| PHASE2/PHASE3 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06784622 | PHASE4 | NOT_YET_RECRUITING | Evaluatıon of the Effect of Pulpotomy Treatments Wıth Dıfferent Bıomaterıals on Postoperatıve Paın In Permanent Molars |
| NCT02286648 | PHASE4 | UNKNOWN | Success Rate Evaluation of Miniature Pulpotomy With MTA in Primary Molars |
| NCT02819648 | PHASE4 | COMPLETED | Oral Glucocorticoids Effect on Post Endodontic Pain |
| NCT04795830 | PHASE4 | COMPLETED | Bioactive Materials in Pulp Therapy of Primary Teeth |
| NCT01420718 | PHASE2/PHASE3 | COMPLETED | Partial Pulpotomy on Caries Free Human Teeth |
| NCT02629042 | PHASE3 | COMPLETED | Efficacy of Oral Prednisolone on Pain Reduction in Emergency Care of Acute Irreversible Pulpitis |
| NCT04365270 | PHASE3 | COMPLETED | Antibacterial Effect and Clinical Performance of Chitosan Modified Glass Ionomer |
| NCT06679075 | PHASE2 | ACTIVE_NOT_RECRUITING | Clinical and Radiographic Evaluation of Propolis As a Hemostatic Agent for Pulpotomy of Mature Permanent Molars with Irreversible Pulpitis Using Two Different Dressing Materials |
| NCT01178203 | PHASE1/PHASE2 | COMPLETED | The Effects of Three Oral Medications on Post-operative Pain Following Endodontic Treatment |
| NCT02601924 | PHASE2 | COMPLETED | Efficacy of Pressure Massage and Topical Gel on Pain During Intra Oral Injections |
| NCT06276842 | PHASE1/PHASE2 | COMPLETED | Efficacy of Combining an Inferior Alveolar Nerve Block With a Buccal Infiltration |
| NCT05557812 | EARLY_PHASE1 | COMPLETED | A Clinical Trial Comparing FS With ZOE and Non-eugenol Based Materials in Primary Teeth Pulpotomies |
| NCT06447753 | Not specified | RECRUITING | COMPARATIVE EVALUATION OF DIRECT PULP CAPPING AND COMPLETE PULPOTOMY IN MATURE PERMANENT MANDIBULAR MOLARS WITH CLINICAL SIGNS INDICATIVE OF MODERATE PULPITIS |
| NCT06468085 | Not specified | NOT_YET_RECRUITING | Evaluation of Pulpotomy Using Two Different Agents in Mature Anterior Teeth With Pulpitis |
| NCT06526572 | Not specified | RECRUITING | Pain Measured by NRS and EEG in Acute Pulpitis |
| NCT06675058 | Not specified | NOT_YET_RECRUITING | Caries Location and Its Effect on the Success Rate of Indirect Pulp Treatment in Primary Molars |
| NCT06844448 | Not specified | RECRUITING | The Effect of Different Risk Factors on the Success Rate of VPT |
| NCT06938191 | Not specified | NOT_YET_RECRUITING | Comparison of Aquaporin -4, -5, -9 and IL-8 Levels in GCF, Dentin Fluid and Pulp Samples |
| NCT07018284 | Not specified | RECRUITING | Postoperative Pain Evaluation After Obturation With Different Sealers |
| NCT07019298 | Not specified | RECRUITING | Success of Endodontic Treatment With Different Obturation Techniques and Sealer Cements |
| NCT07123025 | Not specified | RECRUITING | Outcome of Partial Pulpotomy in Moderate and Severe Pulpitis |
| NCT07130214 | Not specified | ACTIVE_NOT_RECRUITING | The Effect of Genetic Polymorphisms on the Success of Vital Pulp Therapy |
| NCT07242742 | Not specified | RECRUITING | Effectiveness of Pulpotomy vs. Root Canal Treatment in Extremely Deep Caries |
| NCT07379515 | Not specified | NOT_YET_RECRUITING | Effects of Topical Anesthesia Approaches on Dental Pain During and After Restorative Management of Dental Caries |
| NCT07418840 | Not specified | NOT_YET_RECRUITING | Clinical and Radiographic Evaluation of Primary Endodontic Treatment and Non-surgical Endodontic Retreatments |
| NCT07450235 | Not specified | NOT_YET_RECRUITING | Measurement of Pro-resolving Inflammation Biomarkers in Saliva, Gingival Fluid, and Dental Pulp in Patients With Symptomatic Pulpitis and Healthy Controls |
| NCT07452614 | Not specified | RECRUITING | Predicting Vital Pulp Treatment Outcomes in Symptomatic Pulpits Using Metabolic Biomarker |
| NCT07546773 | Not specified | NOT_YET_RECRUITING | Metagenomic Analysis and Postoperative Pain in Infected Root Canals Using Different Irrigation Protocols |
| NCT00748280 | Not specified | COMPLETED | Vital Pulp Therapy to Treat Irreversible Pulpitis |
| NCT00972556 | Not specified | UNKNOWN | Comparison of Mineral Trioxide Aggregate (MTA) and 20% Formocresol (FC) in Pulpotomized Human Primary Molars |
| NCT01530217 | Not specified | COMPLETED | Assessing of Tooth Sensitivity Using Ibuprofen Before in Office-tooth Bleaching |
| NCT02169102 | Not specified | COMPLETED | Effect of Low Power Laser in Tooth Pain Modulation Caused by Irreversible Inflammation |
| NCT02422823 | Not specified | COMPLETED | Anesthetic Efficacy of 1,8mL and 3,6mL of Articaine in Inferior Alveolar Nerve Block in Irreversible Pulpitis |
| NCT02494193 | Not specified | COMPLETED | Indirect Pulp Capping With Resin Modified Glass Ionomer |
| NCT02566486 | Not specified | COMPLETED | Postoperative Pain Intensity After Using Different Instrumentation Techniques: a Randomized Clinical Study |
| NCT02681276 | Not specified | COMPLETED | Clinical and Microbiological Evaluation of 0.5% Versus 3% Sodium Hypochlorite in Root Canal Treatment |
| NCT02745782 | Not specified | UNKNOWN | A Study of the Trigeminal Cardio-Reflex in Endodontic and Other Dental Treatment |
| NCT02940704 | Not specified | COMPLETED | Assessment of Postoperative Pain After Using Reciproc Versus One Shape NiTi Systems |
| NCT02940782 | Not specified | UNKNOWN | Comparison Between Reciproc and Oneshape Systems |
| NCT02967081 | Not specified | COMPLETED | Evaluation of Dentinal Fluid for the Presence of Matrix Metalloproteinase 9 (MMP-9) in Pulpal Inflammation |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| PREDNISOLONE | 4 | 2 |
| ARTICAINE | 4 | 1 |
| HYDROGEN PEROXIDE | 4 | 1 |
| SODIUM HYPOCHLORITE | 4 | 1 |
| TITANIUM DIOXIDE | 4 | 1 |
| TRAMADOL | 4 | 1 |
| FERRIC SULFATE | 3 | 2 |
| CHITOSAN LOW MOLECULAR WEIGHT (20-200 MPA.S) | 3 | 1 |
| CHLORHEXIDINE DIACETATE | 3 | 1 |
| STARCH | 3 | 1 |
| EFROFILCON A | 1 | 1 |
| CHEMBL541521 | 0 | 1 |
| (R,R)-TRAMADOL | 0 | 1 |